Collectionner le produit
Détails du produit
- ItemsSize 2mgSize 10mg (5mg × 2)Particle size2 μm2 μmPhysical appearancePowder mixturePowder mixtureCapacity>133.3 pmol (20μg) Anti-FAP Ab/mg beads>133.3 pmol (20 μg) Anti-FAP Ab/mg beadsFormulationPBS, pH7.4, with 10% TrehalosePBS, pH7.4, with 10% TrehaloseReconstitution2 mL ultrapure water (1 mg beads/mL)2 mL μLtrapure water (1 mg beads/mL)
Product Description
The biotinylated FAP protein was conjugated to streptavidin magnetic beads. This pre-coupled magnetic bead product can capture the anti-FAP antibody from various assay systems. The beads are in uniform size, narrow size distribution with large surface area and unique surface coating, which can help you get the best performance and highly reproducible results. This FAP coupled magnetic beads will bring great convenience with minimum non-specific binding and developed protocols. This ready-to-use product could greatly save your time and hassle.
Application
This product is intended for immunocapture, biopanning. This is a non-sterile product.
* The Isotype control (Cat. No. SMB-B01) is sold separately.
Reconstitution
See Certificate of Analysis (CoA) for detailed instruction.
Storage
Upon receipt, please store the Beads at -20°C. The shelf life is 1 year at -20 °C. Once reconstitution, please aliquote and store under -70°C for no more than 3 months, and avoid repeated freeze-thaw cycles. Immediate use after reconstitution is highly recommended.
Please avoid more than 3 freeze-thaw cycles once reconstitution, immediate use after reconstitution is highly recommended.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
Typical Data
Immobilized 33.8μg Biotinylated Human FAP protein to 1mg Beads can bind the Anti-FAP Antibody with an EC50 0.13 μg/mL (QC tested).
Protocol
Avis des utilisateurs Publier un commentaire
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
Prolyl endopeptidase FAP
- Catégorie：
- Nombre de médicaments répertoriés：
0 Détails
- Nombre de médicaments cliniques：
88 Détails
- Étape de développement la plus élevée：
Phase 3 Clinical
Contact Us
Drug Candidate Licensing
